Advertisement
AZN vs SABA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZN is a Buy and SABA is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZN’s FA Score shows that 2 FA rating(s) are green while.
- AZN’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZN’s TA Score shows that 4 TA indicator(s) are bullish.
- AZN’s TA Score: 4 bullish, 5 bearish.
Price Growth
AZN (@Pharmaceuticals: Major) experienced а +5.78% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +4.07%. For the same industry, the average monthly price growth was +1.80%, and the average quarterly price growth was +20.38%.
Reported Earning Dates
AZN is expected to report earnings on Feb 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+4.07% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
AZN | ||
|---|---|---|
OUTLOOK RATING 1..100 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | |
PROFIT vs RISK RATING 1..100 | 27 | |
SMR RATING 1..100 | 45 | |
PRICE GROWTH RATING 1..100 | 44 | |
P/E GROWTH RATING 1..100 | 50 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| AZN | SABA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 47% | 2 days ago 89% |
| Stochastic ODDS (%) | 2 days ago 43% | 2 days ago 82% |
| Momentum ODDS (%) | 2 days ago 61% | 2 days ago 78% |
| MACD ODDS (%) | 2 days ago 55% | 2 days ago 72% |
| TrendWeek ODDS (%) | 2 days ago 56% | 2 days ago 76% |
| TrendMonth ODDS (%) | 2 days ago 56% | 2 days ago 77% |
| Advances ODDS (%) | 4 days ago 55% | 5 days ago 78% |
| Declines ODDS (%) | 22 days ago 43% | 2 days ago 74% |
| BollingerBands ODDS (%) | 2 days ago 40% | 2 days ago 60% |
| Aroon ODDS (%) | 2 days ago 41% | 2 days ago 73% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| UJAN | 42.42 | -0.17 | -0.41% |
| Innovator US Equity Ultra Buff ETF™ Jan | |||
| PSFJ | 32.58 | -0.21 | -0.63% |
| Pacer Swan SOS Flex (July) ETF | |||
| PCEF | 19.86 | -0.14 | -0.70% |
| Invesco CEF Income Composite ETF | |||
| IXUS | 84.31 | -0.96 | -1.13% |
| iShares Core MSCI Total Intl Stk ETF | |||
| HOOW | 58.23 | -6.59 | -10.16% |
| Roundhill HOOD WeeklyPay ETF | |||
AZN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AZN has been loosely correlated with GSK. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if AZN jumps, then GSK could also see price increases.
SABA and
Correlation & Price change
A.I.dvisor tells us that SABA and JPM have been poorly correlated (+7% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SABA and JPM's prices will move in lockstep.
| Ticker / NAME | Correlation To SABA | 1D Price Change % | ||
|---|---|---|---|---|
| SABA | 100% | -0.86% | ||
| JPM - SABA | 7% Poorly correlated | -3.41% | ||
| AZN - SABA | 5% Poorly correlated | +1.06% |